CHICAGO, ILLINOIS — Neuromod Devices, the medical technology company behind Lenire, an FDA-approved tinnitus treatment device, has announced its sponsorship of the 10th Annual LexCare Hearing Foundation Hearoes Tour. The initiative aims to expand awareness of and access to hearing and tinnitus care for veterans across the United States.
The Hearoes Tour is a national outreach program that delivers free hearing health resources, screenings, and education to veteran communities. Hosting more than 200 events annually, the tour seeks to remove barriers to care by simplifying access, addressing affordability, and raising awareness about the consequences of untreated hearing loss. Since its inception, the Hearoes Tour has conducted over 33,000 hearing screenings and held more than 1,000 free hearing health events.
According to Jaime Motes, Founder and Director of the LexCare Hearing Foundation, nearly 40% of veterans served through the program report experiencing tinnitus. “For years, we had no real solution to offer them,” said Motes. “Thanks to our partnership with Lenire, we can now connect veterans with a life-changing tinnitus treatment option.”
Tinnitus remains the most common service-connected disability among U.S. veterans, with an estimated $6.6 billion in compensation provided by the Department of Veterans Affairs (VA) in 2024. Lenire became a treatment option for approximately 3.2 million veterans living with tinnitus following Neuromod’s acquisition of a Federal Supply Schedule (FSS) 65 II Medical Equipment & Supply Contract. To date, 50 VA facilities have been trained to provide Lenire, with additional sites scheduled for training in 2025.
“Sponsoring the 10th Annual Hearoes Tour advances our commitment to supporting veterans by increasing awareness and accessibility to effective tinnitus treatment”
–Eric Timm, CEO of Neuromod USA and President of Global Commercial Operations at Neuromod Devices.
Real-world data from U.S. clinics using Lenire continues to demonstrate its efficacy. One such study, conducted by Alaska Hearing & Tinnitus Center, showed that 91.5% of 220 patients experienced clinically significant improvement. These findings align with results from Lenire’s clinical trials, which formed the basis of its De Novo FDA approval and were featured in Nature Communications, where the trial results were highlighted on the cover and ranked in the 99th percentile of over 250,000 Nature articles.
-
https://www.benefits.va.gov/REPORTS/abr/docs/2024-abr.pdf
-
https://doi.org/10.1101/2024.08.22.24312175
